[go: up one dir, main page]

WO2002014361A3 - NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER - Google Patents

NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER Download PDF

Info

Publication number
WO2002014361A3
WO2002014361A3 PCT/US2001/025782 US0125782W WO0214361A3 WO 2002014361 A3 WO2002014361 A3 WO 2002014361A3 US 0125782 W US0125782 W US 0125782W WO 0214361 A3 WO0214361 A3 WO 0214361A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
catrf2e11
useful
detection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/025782
Other languages
French (fr)
Other versions
WO2002014361A2 (en
Inventor
Arthur B Raitano
Pia M Challita-Eid
Mary Faris
Douglas C Saffran
Daniel E H Afar
Elana Levin
Rene S Hubert
Wangmao Ge
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to AU2001285018A priority Critical patent/AU2001285018A1/en
Publication of WO2002014361A2 publication Critical patent/WO2002014361A2/en
Anticipated expiration legal-status Critical
Publication of WO2002014361A3 publication Critical patent/WO2002014361A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A novel gene (designated 83P2H3) and its encoded protein are described. While 83P2H3 exhibits tissue specific expression in normal adult tissue, it is a aberrantly expressed in prostate cancer. Consequently, 83P2H3 provides a diagnostic and/or therapeutic target of cancer. The 83P2H3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
PCT/US2001/025782 2000-08-17 2001-08-17 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER Ceased WO2002014361A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285018A AU2001285018A1 (en) 2000-08-17 2001-08-17 Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22632900P 2000-08-17 2000-08-17
US60/226,329 2000-08-17

Publications (2)

Publication Number Publication Date
WO2002014361A2 WO2002014361A2 (en) 2002-02-21
WO2002014361A3 true WO2002014361A3 (en) 2003-09-25

Family

ID=22848496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025782 Ceased WO2002014361A2 (en) 2000-08-17 2001-08-17 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER

Country Status (2)

Country Link
AU (1) AU2001285018A1 (en)
WO (1) WO2002014361A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952586B2 (en) 2017-11-30 2024-04-09 Hoffmann-La Roche Inc. B-cell cultivation method

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134178D1 (en) * 2000-07-28 2008-07-03 Ulrich Wissenbach TRP8 CANCER MARKER
CA2512392A1 (en) * 2003-01-08 2004-07-29 Toudai Tlo, Ltd. Human calcium transporter 1 gene, screening method of calcium absorption regulating factor, and calcium absorption regulating factor
EP2518149B1 (en) 2006-02-22 2015-12-16 International Institute of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
WO2022120423A1 (en) * 2020-12-08 2022-06-16 James Cook University Peptides and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PENG J ET AL: "MOLECULAR CLONING AND CHARACTERIZATION OF A CHANNEL-LIKE TRANSPORTER MEDIATING INTESTINAL CALCIUM ABSORPTION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 32, 6 August 1999 (1999-08-06), pages 22739 - 22746, XP000960319, ISSN: 0021-9258 *
WISSENBACH U ET AL: "Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 22, 1 June 2001 (2001-06-01), pages 19461 - 19468, XP002222954, ISSN: 0021-9258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952586B2 (en) 2017-11-30 2024-04-09 Hoffmann-La Roche Inc. B-cell cultivation method

Also Published As

Publication number Publication date
WO2002014361A2 (en) 2002-02-21
AU2001285018A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
WO2004016799A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER
WO2002016598A3 (en) Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
WO2003022995A3 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
WO2003040340A3 (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
WO2003050255A3 (en) Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
WO2004098515A3 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
WO2002014361A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
WO2002072785A3 (en) Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
WO2004067716A3 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2002083919A3 (en) Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
WO2004072263A3 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2006055004A8 (en) Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
WO2002014501A3 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
WO2002018578A3 (en) Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
WO2001079557A3 (en) Gtp-binding protein useful in treatment and detection of cancer
WO2002092842A3 (en) Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
WO2002083928A3 (en) Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
WO2004050828A3 (en) Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
WO2002095009A3 (en) Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
WO2004021977A3 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
WO2001096391A3 (en) 55p4h4: gene expressed in various cancers
WO2000065053A3 (en) Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma
WO2002012329A3 (en) Compositions and methods for the therapy and diagnosis of head and neck cancer
WO2002024057A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP